Reports
The following list of reports reflects the latest in findings and outcomes in medical research as presented at major medical meetings and published peer-reviewed medical journals. In this section you can view reports from important congresses as well as summaries of some recently published journal articles. Please let us know if you have a particular area of interest you would like to see covered.
MEDICAL OPTIONS in Neuro-Oncology
Currrent Trends and Future Perspectives in Glioblastoma Multiforme - Reviews from published literature
Recurrence Patterns in Gliomas Dr. Normand Laperrière, University of Toronto Management of Recurrent Glioblastoma Multiforme Dr. Rolando Del Maestro, McGill University Rechallenge with Temozolomide: Dosing Strategies Dr. James R. Perry,...
JOURNAL CLUB - Oncology
Enhancing Progression-free Survival in Metastatic Breast Cancer: Efficacy of VEGF Inhibition and Taxane-based Therapy
At the end of this report, you can view Prof. David Miles' ASCO presentation on the AVADO study.
Editorial Overview: John R. Mackey, MD, FRCPC Professor of Oncology, University of Alberta, Edmonton, Alberta Breast cancer affects approximately 21,000 Canadian women a year, and nearly 5400 die from metastatic disease. While mortality...
PRIORITY PRESS - National Oncology Pharmacy Symposium 2008
Cardiac Management During Adjuvant Breast Cancer Therapy: Canadian Working Group Recommendations
Calgary, Alberta / October 17-19, 2008
For the 20% to 25% of women with HER2-positive breast cancer, there is a higher risk of early relapse and a reduced overall survival rate. However, the overexpression of the HER2 protein also represents a therapeutic opportunity. The...
PRIORITY PRESS - National Oncology Pharmacy Symposium 2008
Prevention and Management of Chemotherapy-induced Nausea and Vomiting
Calgary, Alberta / October 17-19, 2008
For the past 25 years, nausea and vomiting have consistently been rated by patients as among the most severe side effects of chemotherapy, stated clinical oncology pharmacist Scott Edwards, PharmD, Eastern Health, St. John’s,...
33rd Congress of the European Society for Medical Oncology
Optimizing Efficacy and Manageable Toxicity in Metastatic Breast Cancer
Stockholm, Sweden / September 12-16, 2008
Stockholm - New results of a multicentre phase III clinical trial have demonstrated that an encapsulated form of doxorubicin is highly effective and is associated with a low level of toxicity when administered to women with metastatic...
33rd Congress of the European Society for Medical Oncology
Optimizing Targeted Therapy of Renal Cell Carcinoma
Stockholm, Sweden / September 12-16, 2008
Stockholm - After two decades with nothing new to offer patients, oncologists now have four new approved drugs for treatment of advanced renal cell carcinoma (RCC). Although the role of these agents in RCC and other types of cancer is...
33rd Congress of the European Society for Medical Oncology
High Activity Rates Establish Targeted Therapies as Standard in Renal Cell Carcinoma and GIST
Stockholm, Sweden / September 12-16, 2008
Stockholm - The survival rates associated with therapies targeted at specific molecular processes in renal cell carcinoma (RCC) and gastrointestinal stromal tumours (GIST) are unprecedented. The activity in these two malignancies provides...
33rd European Society for Medical Oncology Congress
Redefining Optimal Breast Cancer Management: Progress with Adjuvant Endocrine Therapy and Targeted Agents
Stockholm, Sweden / September 12-16, 2008
Stockholm - Evolving breast cancer strategies are being driven from two ends of disease control. Of immediate relevance, a consensus about how to best employ adjunctive endocrine therapy is being driven by a series of large studies...
33rd Congress of the European Society for Medical Oncology
Guidelines Support for Low Molecular-weight Heparin for Long-term Recurrent VTE Prevention in Cancer Patients
Stockholm, Sweden / September 12-16, 2008
Stockholm - The risk posed by cancer for venous thromboembolism (VTE) and pulmonary embolism appears to be insufficiently appreciated. In patients hospitalized for cancer, anticoagulation is a recognized standard of care, but the much...